Research and Markets: Global Moderate Pain Therapeutics Pipeline Review, H2 2015
November 27 2015 - 6:17PM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/8dmr3h/moderate_pain)
has announced the addition of the "Moderate Pain - Pipeline Review,
H2 2015" report to their offering.
This report provides comprehensive information on the
therapeutic development for Moderate Pain, complete with
comparative analysis at various stages, therapeutics assessment by
drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type, along with the latest updates, and
featured news and press releases. It also reviews key players
involved in the therapeutic development for Moderate Pain and
special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and helps to
create effective counter strategies to gain competitive advantage.
It strengthens R&D pipelines by identifying new targets and
MoAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Amorsa Therapeutics Inc.
- Charleston Laboratories, Inc.
- Egalet Corporation
- Elite Pharmaceuticals, Inc.
- KemPharm, Inc.
- Laboratorios Del Dr. Esteve S.A.
- Lumosa Therapeutics Co., Ltd.
- Nektar Therapeutics
- Pacira Pharmaceuticals, Inc.
- Pain Therapeutics, Inc.
- Pfizer Inc.
- Purdue Pharma L.P.
- Relmada Therapeutics, Inc.
- Teva Pharmaceutical Industries Limited
- Trevena, Inc.
For more information visit
http://www.researchandmarkets.com/research/8dmr3h/moderate_pain.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151127005394/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor EST Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Central Nervous System